Team:Slovenia/Conclusions
From 2008.igem.org
(Difference between revisions)
(14 intermediate revisions not shown) | |||
Line 161: | Line 161: | ||
--> | --> | ||
<html><center> | <html><center> | ||
- | <font size=" | + | <font size="6" color="#C73E4A"><i>Conclusions</i></font> |
</center></html> | </center></html> | ||
Line 167: | Line 167: | ||
---- | ---- | ||
<html> | <html> | ||
- | <strong>Achievements< | + | <strong><font size="4">Achievements <font size="2"><br /></strong> |
- | <div style="text-align:justify" | + | <div style="text-align:justify"> |
<ul> | <ul> | ||
- | <li>We have demonstrated the power of modular building blocks approach of synthetic biology (IMMUNOBRICKS) for the rational design of vaccines</li> | + | <li>We have demonstrated <b>the power of modular building blocks approach of synthetic biology (IMMUNOBRICKS)</b> for the rational design of vaccines</li> |
- | <li>We have designed a new type of vaccine against H. pylori based on chimeric flagellin that combines activation of innate and adaptive immunity | + | <li>We have designed a new type of vaccine against <i>H. pylori</i> based on the chimeric flagellin that <b>combines activation of innate and adaptive immunity within the same molecule</b> |
<ul> | <ul> | ||
<li>Chimeric flagellins were produced in bacteria, purified and characterized</li> | <li>Chimeric flagellins were produced in bacteria, purified and characterized</li> | ||
- | <li>Engineered flagellins activate TLR5 as opposed to the native H. pylori flagellin</li> | + | <li>Engineered <i>H. pylori</i> flagellins activate TLR5 as opposed to the native <i>H. pylori</i> flagellin</li> |
- | <li> | + | <li>Three different implementations of chimeric flagellin vaccines were prepared</li> |
- | <li> | + | <li>Chimeric flagellin is localized at the bacterial surface</li> |
- | <li>DNA construct based on chimeric flagellin | + | <li>DNA construct based on chimeric flagellin causes transactivation of TLR5 on neighboring cells (demonstration of the <b>feasibility of introduction of DNA into the epithelial cells to activate the underlying dendritic cells)</b></li> |
</ul> | </ul> | ||
</li> | </li> | ||
<li>Antigen-TLR fusions are functional and their localization can be modulated by the selection of transmembrane segment</li> | <li>Antigen-TLR fusions are functional and their localization can be modulated by the selection of transmembrane segment</li> | ||
- | <li>Various DNA vaccine constructs have been successfully introduced by electroporation intramuscularly or subcutanelously and expression of the fusion protein in the target tissue in vivo was demonstrated</li> | + | <li>Various DNA vaccine constructs have been successfully introduced by electroporation intramuscularly or subcutanelously and expression of the fusion protein in the target tissue <i>in vivo</i> was demonstrated</li> |
+ | <li>Two chimeric recombinant protein vaccines showed <b>an intense IgG antibody response in mice</b> and <b>immunized sera also reacted with live and heat-killed <i>H. pylori</i></b> implying that they recognize epitopes of <i>H. pylori</i>.</li> | ||
</ul> | </ul> | ||
<br /><br /> | <br /><br /> | ||
- | <strong>What remains to be done ?< | + | <strong><font size="4">What remains to be done?<font size="2"><br /></strong> |
- | + | ||
<ul> | <ul> | ||
- | <li>Complete animal studies: demonstrate the | + | <li>Complete the animal studies: demonstrate the prophilactic efficiency of our vaccines to prevent colonization, and therapeutic value to eradicate existing infection as well as evaluate effects of vaccinations on histology of gastric mucosa……</li> |
<li>Demonstrate the efficiency of bacterial implementation of flagellin-like vaccine on lyophilized bacterial ghosts (more safe and stable vaccine), particularly for oral and mucosal vaccination – prospects for application in third world countries</li> | <li>Demonstrate the efficiency of bacterial implementation of flagellin-like vaccine on lyophilized bacterial ghosts (more safe and stable vaccine), particularly for oral and mucosal vaccination – prospects for application in third world countries</li> | ||
<li>Analyze different combinations of antigen-TLRs to obtain optimal immune stimulation (TLR synergy)</li> | <li>Analyze different combinations of antigen-TLRs to obtain optimal immune stimulation (TLR synergy)</li> | ||
<li>Repeat all experiments with many controls, in comparison to currently used adjuvants etc</li> | <li>Repeat all experiments with many controls, in comparison to currently used adjuvants etc</li> | ||
+ | <li>... ... ars longa, vita brevis</li> | ||
</ul><br /><br /> | </ul><br /><br /> | ||
- | Prospects | + | <strong><font size="4">Prospects<font size="2"><br /></strong> |
<ul> | <ul> | ||
- | <li>Functional vaccine against H. pylori would be definitely welcome</li> | + | <li>Functional vaccine against <i>H. pylori</i> would be definitely welcome</li> |
- | <li>The approach with chimeric flagellins could be used against other flagellated bacteria whose flagellin does not activate innate system (Bartonella, Campylobacter, Borellia...)</li> | + | <li>The approach with chimeric flagellins could be used against other flagellated bacteria whose flagellin does not activate innate immune system (<i>Bartonella, Campylobacter, Borellia</i>...)</li> |
<li>Could vaccines based on antigen-TLR fusions be used as tumor vaccines as well?</li> | <li>Could vaccines based on antigen-TLR fusions be used as tumor vaccines as well?</li> | ||
- | |||
- | |||
- | |||
</ul> | </ul> | ||
</div> | </div> |
Latest revision as of 04:02, 30 October 2008
|
|
| |
|
|
Achievements
What remains to be done?
Prospects
|
|
|